NORPLANT Implants and the TCu 200 IUD: A Comparative Study in Ecuador

Marangoni, P; Cartagena, Sumner; Alvarado, Javier Orozco; Dı́az, Juan; Faúndes, Aníbal

doi:10.2307/1965497

Cited by 15 publications

(11 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In every follow-up year the Norplant group had fairly high risk; in the third year the risk was 34 times that of the IUD group. Other researchers report spotting (intermenstrual bleeding) and decrease in length of menstruation, rather than less menstrual flow than usual [5,[60][61][62].…”

Section: Resultsmentioning

confidence: 99%

A cohort study of Norplant implant: Side-effects and acceptance

1995

Adv Contracept

View full text Add to dashboard Cite

show abstract

Section: Resultsmentioning

confidence: 99%

A cohort study of Norplant implant: Side-effects and acceptance

1995

Adv Contracept

View full text Add to dashboard Cite

show abstract

“…It was not applicable to collect this information in three studies in which the outcome of interest was pregnancy after discontinuation of method. 72,75,76 In the remaining 30 studies, eight reported whether or not the women were counselled, 44,47,63,66,68,70,79,82 16 provided information on insertion dates, 37,47,52,55,56,62,65,68,77,81 and three stated that insertions were conducted by professionals who had received some training on implant insertion. 47,77,82 Information on insertion date was more frequently reported for RCTs than for non-RCT comparisons (73% 37,47,52,55,56 versus 31% 62,65,68,77,81 ), but RCTs were less likely than non-RCTs to state whether the women had received counselling (7% 47 versus 50% 44,62,66,68,70,79,80,82 ).…”

Section: Chaptermentioning

confidence: 99%

Implantable contraceptives (subdermal implants and hormonally impregnated intrauterine systems) versus other forms of reversible contraceptives: two systematic reviews to assess relative effectiveness, acceptability, tolerability and cost-effectiveness.

French

Cowan²,

Mansour³

et al. 2000

Health Technology Assessment

109

View full text Add to dashboard Cite

et al. Implantable contraceptives (subdermal implants and hormonally impregnated intrauterine systems) versus other forms of reversible contraceptives: two systematic reviews to assess relative effectiveness, acceptability, tolerability and cost-effectiveness. Health Technol Assess 2000;4(7). Health Technology Assessment is indexed in Index Medicus/MEDLINE and Excerpta Medica/ EMBASE. Copies of the Executive Summaries are available from the NCCHTA website (see overleaf). NHS R&D HTA Programme T he overall aim of the NHS R&D Health Technology Assessment (HTA) programme is to ensure that high-quality research information on the costs, effectiveness and broader impact of health technologies is produced in the most efficient way for those who use, manage and work in the NHS. Research is undertaken in those areas where the evidence will lead to the greatest benefits to patients, either through improved patient outcomes or the most efficient use of NHS resources. The Standing Group on Health Technology advises on national priorities for health technology assessment. Six advisory panels assist the Standing Group in identifying and prioritising projects. These priorities are then considered by the HTA Commissioning Board supported by the National Coordinating Centre for HTA (NCCHTA). This report is one of a series covering acute care, diagnostics and imaging, methodology, pharmaceuticals, population screening, and primary and community care. It was identified as a priority by the Pharmaceutical Panel and funded as project number 95/41/01. The views expressed in this publication are those of the authors and not necessarily those of the Standing Group, the Commissioning Board, the Panel members or the Department of Health. The editors wish to emphasise that funding and publication of this research by the NHS should not be taken as implicit support for the recommendations for policy contained herein. In particular, policy options in the area of screening will be considered by the National Screening Committee. This Committee, chaired by the Chief Medical Officer, will take into account the views expressed here, further available evidence and other relevant considerations. Reviews in Health Technology Assessment are termed 'systematic' when the account of the search, appraisal and synthesis methods (to minimise biases and random errors) would, in theory, permit the replication of the review by others. Criteria for inclusion in the HTA monograph series Reports are published in the HTA monograph series if (1) they have resulted from work either prioritised by the Standing Group on Health Technology, or otherwise commissioned for the HTA programme, and (2) they are of a sufficiently high scientific quality as assessed by the referees and editors.

show abstract

“…Irregular bleeding is the commonest unwanted effect 7 , 8 , 13. Between 50% and 80% of women report a change in bleeding pattern 7 , 8 , 11.…”

Section: Unwanted Effectsmentioning

confidence: 99%

▼Norplant - a contraceptive implant

1994

DTB

View full text Add to dashboard Cite

Norplant, a progestagen implant designed to provide contraception for five years, was launched in the UK in October 1993. Almost 3 million women world wide are using it. The manufacturer claims that Norplant is "one of the most effective and practical forms of contraception for any woman who wants long-term reliability, convenience and the opportunity to change her mind". In this article we assess its use.

show abstract

NORPLANT Implants and the TCu 200 IUD: A Comparative Study in Ecuador

Cited by 15 publications

References 0 publications

A cohort study of Norplant implant: Side-effects and acceptance

A cohort study of Norplant implant: Side-effects and acceptance

Implantable contraceptives (subdermal implants and hormonally impregnated intrauterine systems) versus other forms of reversible contraceptives: two systematic reviews to assess relative effectiveness, acceptability, tolerability and cost-effectiveness.

▼Norplant - a contraceptive implant

Contact Info

Product

Resources

About